Literature DB >> 8981568

Botulinum toxin as a therapeutic agent.

J K Tsui1.   

Abstract

Botulinum toxin is a presynaptic neuromuscular blocking agent that, when injected intramuscularly in minute quantities, can produce selective muscle weakness. This property is employed therapeutically to provide symptomatic relief in conditions related to excessive muscle activities in strabismus, blepharospasm, hemifacial spasm, cervical dystonia, spasmodic dysphonia (adductor type), and jaw closing dystonia. It is investigational for a long list of medical conditions. It is a marketed drug in a number of countries in the world, but its use has only been approved by different regulatory agencies for use in a limited number of conditions. The long-term effects, appropriate dose for children, and in pregnancy, and maximum dose without causing toxicity remain unclear.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981568     DOI: 10.1016/s0163-7258(96)00091-5

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  13 in total

1.  Achalasia in a patient with gastroesophageal varices: problematic treatment decisions.

Authors:  Hugo Pinillos; Peter Legnani; Thomas Schiano
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

2.  Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.

Authors:  Gael J Yonnet; Anette S Fjeldstad; Noel G Carlson; John W Rose
Journal:  Int J MS Care       Date:  2013

3.  Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial.

Authors:  M F Vaezi; J E Richter; C M Wilcox; P L Schroeder; S Birgisson; R L Slaughter; R E Koehler; M E Baker
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 4.  Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.

Authors:  Areeba Sadiq; Benjamin M Brucker
Journal:  Curr Urol Rep       Date:  2015-07       Impact factor: 3.092

5.  Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.

Authors:  Jaeyoon Byun; Seongsung Kwak; Jin-Hee Kwon; Minhee Shin; Dong-Kyu Lee; Chang-Hoon Rhee; Won-Ho Kang; Jae-Wook Oh; Deu John M Cruz
Journal:  Toxins (Basel)       Date:  2022-05-25       Impact factor: 5.075

Review 6.  Botulinum toxin therapy: functional silencing of salivary disorders.

Authors:  A Lovato; D A Restivo; G Ottaviano; G Marioni; R Marchese-Ragona
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-04       Impact factor: 2.124

7.  The Use of Botulinum Toxins for Chronic Pain and Headaches.

Authors:  Charles E. Argoff
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

Review 8.  Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment.

Authors:  Carlos Henrique Ferreira Camargo; Lígia Cattai; Hélio Afonso Ghizoni Teive
Journal:  Toxins (Basel)       Date:  2015-06-23       Impact factor: 4.546

Review 9.  Use of Botulinum Neurotoxin in Ophthalmology.

Authors:  Emel Başar; Ceyhun Arıcı
Journal:  Turk J Ophthalmol       Date:  2016-12-01

10.  Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life.

Authors:  Eman M I Moawad; Enas Abdallah Ali Abdallah
Journal:  Glob Pediatr Health       Date:  2015-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.